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The pituitary gland is considered the master gland of the endocrine system as it 
releases hormones that stimulate and control many important endocrine glands such 
as the thyroid, adrenal, ovaries and testes (1).  It is a small pea-sized gland that weighs 
about 500 mg. The size is variable and is usually larger in women, especially during 
pregnancy and lactation. It is connected to the hypothalamus by a stalk and is 
embedded in a  bony structure called the Sella turcica (Turkish saddle) (2).  The 
structures lateral to the pituitary gland are the cavernous sinuses, which contain 
cranial nerves III (oculomotor), IV (trochlear), VI (abducens), V1 (ophthalmic branch 
of the trigeminal nerve), and V2 (maxillary branch of the trigeminal nerve) as well as 
the   carotid artery that lies medical to the cranial nerves (3). 
The release of pituitary hormones is under the influence of hypothalamic 
neurohormones which are secreted from the median eminence (a site where axon 
terminals emanate from the hypothalamus) and that reach the adenohypophysis via a 
portal venous system (4). 
The anterior part of the pituitary gland secretes trophic hormone: growth hormone 
(GH), prolactin, adrenocorticotrophin (ACTH), thyrotrophin (TSH), and the 
gonadotrophins (FSH and LH) whilst the posterior part secretes vasopressin and 
oxytocin (5). 
 
1.2 Pituitary adenoma 
 
The pituitary gland can be affected by many diseases that can influence hormone 
secretion (hyposecretion or hypersecretion)(see table 1). An adenoma in the pituitary 
gland is one of the more common causes of pituitary dysfunction. 
Pituitary adenomas account for approximately 14% of CNS neoplasms and the 
prevalence in population is about 17% (6)(7). The non-functional adenomas (adenoma 
not secreting hormone) are about 36%- 54%, the functional adenomas (adenoma 
secreting hormone) about 46%- 64% (8)(9). 
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The exact cause of pituitary adenoma is unknown, and most cases of adenomas are 
sporadic. The genetic mutations are a rare cause of some pituitary adenomas (multiple 
endocrine neoplasia type 1 and 4, Carney complex, familial isolated pituitary 
adenomas) (10). 
 In one large population-based study from Northern Finland included the adenomas 
that diagnosed between 1992 and 2007 the incidence rate per 100,00 as follows (11) 
●All pituitary adenomas – 4.0
●Lactotroph adenomas – 2.2
●Clinically non-functioning adenomas – 1.0
●Somatotroph adenomas – 0.34
●Corticotroph adenomas – 0.17
Pituitary tumours are classified by size and the cell of origin. Tumour less than 10 mm 
are classified as microadenomas, and lesions larger than 10 mm are classified as 
macroadenomas. 
1.3 Non-functioning pituitary adenoma 
Non-functioning pituitary adenomas are about 43.1% of all adenomas with most of 
them being classified as gonadotroph adenomas (70-90 %) (9). 
Patients usually present to healthcare workers when they develop a hormone 
disturbance or a neurologic symptom such as impaired vision (bitemporal hemianopsia 
and diminished visual acuity), nonspecific headache, diplopia, cerebrospinal fluid 
rhinorrhoea, or rarely pituitary apoplexy (12). Some patients are incidentally found to 
have a non-functional pituitary adenoma  when magnetic resonance imaging (MRI) is 
done for another reason (13). 
At diagnosis, about 60 % of patients have some symptoms of hypopituitarism as a 
result of compression of the tumour with the gonadotropins the most common 
hormones affected. Symptoms are usually non-specific (fatigue and lethargy) and not 
severe enough for the patient to seek medical attention (14). 
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Patients with neurological symptoms such as a visual field abnormality, usually have 
transsphenoidal surgery as their initial therapy. The choice of surgical procedure, 
microscopic or endoscopic, depends upon the neurosurgeon's experience (15). 
Radiation therapy is indicated if there is significant residual tumour 6-12 months after 
surgery or if there is significant regrowth  of the tumour after surgery (16).  It is essential 
to replace the specific hormone deficiencies and lifetime re-evaluation is needed. 
 
1.4 Cushing’s disease 
 
Cushing’s syndrome due to an ACTH-secreting pituitary adenoma (Cushing’s disease) 
is 5-6 times more common than other causes of Cushing's syndrome. The incidence 
of Cushing's disease is about 5 to 25 per million per year and in one population-based 
study the incidence was much lower (1.2 to 2.4 per million per year) (17). 
The clinical features that most implicate the presence of hypercortisolism include 
proximal muscle weakness, wide purplish striae, bruising with no obvious trauma and 
thin skin (18). 
Establishing the diagnosis of Cushing's syndrome can be complex and includes 
measurement of late-night salivary cortisol (two measurements) and  24-hour urinary 
cortisol excretion (two measurements) as well as an, an overnight 1 mg 
dexamethasone suppression test (DST)  (18). Next steps would include measurement 
of serum ACTH to determine whether the hypercortisolism is ACTH-dependent or 
ACTH-independent and imaging, a pituitary MRI scan for ACTH-dependent 
hypercortisolism of an adrenal CT scan for ACTH-independent hypercortisolism.    In 
some cases, a high dose DST and/or inferior petrosal sinus sampling would be 
required to exclude ectopic production of ACTH.  
The goal of treatment for all patients with Cushing's syndrome is to achieve 
normalization of serum levels of cortisol and subsequent reversal of 
Cushingoid signs/symptoms and co-morbidities (19). 
The best modality for potential cure for Cushing's disease (ACTH-producing pituitary 
tumour) is transsphenoidal micro-adenectomy when possible, but medical therapy is 
often required when surgery is delayed, contraindicated, or unsuccessful. Adrenal 
enzyme inhibitors are the most used drugs, other drugs that can be used include 
adrenolytic agents, drugs that target the pituitary, and glucocorticoid-receptor 
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Acromegaly is the clinical syndrome characterized by excessive secretion 
of somatotrophin (GH). The incidence of acromegaly is 6-8 per million people annually 
and the mean age at diagnosis is 40 to 45 years. A Somatotroph adenoma is 
the commonest cause of acromegaly, it accounts for roughly one-third of all hormone-
secreting pituitary adenomas and 75 % of patients have macroadenomas (tumour 
diameter 10 mm or greater). When GH excess occurs before fusion of the epiphyseal 
growth plates it causes pituitary gigantism in children and adolescent (21). 
About 40% of patients with acromegaly have an activating mutation of the alpha 
subunit of the guanine nucleotide stimulatory protein (Gs-alpha) gene (22). 
Progression of the disease is insidious with many patients only being diagnosed after 
a mean time of 12 years(23). The most common symptoms are headache (60 %) and  
visual symptoms (10 %) (24). 
Long-term over-secretion of growth hormone (GH) and insulin-like growth factor-1 
(IGF-1) results in overgrowth of many tissues, including connective tissue, cartilage, 
bone, skin, and visceral organs. Almost all patients with acromegaly have acral and 
soft tissue overgrowth and skin thickening. The characteristic signs are an enlarged 
jaw (macrognathia) and enlarged swollen hands and feet. Major causes of mortality 
are cardiovascular abnormalities including hypertension, left ventricular hypertrophy, 
and cardiomyopathy. Insulin resistance is common among patients with acromegaly, 
frank diabetes occurs in 10 to 15 % of cases, and impaired glucose tolerance in a 
further 50 %(25). Other systemic complications include sleep apnoea, metabolic 
disorders, and colon neoplasia. 
The insulin-like growth factor-1 (IGF-1) concentration is high in acromegaly.  
Anormal serum IGF-1 concentration is robust evidence that the patient does not have 
acromegaly. Failure to suppress growth hormone during an oral glucose tolerance test 
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confirms the diagnosis. Once that diagnosis of acromegaly is confirmed a pituitary MRI 
scan is needed to localize the lesion. A normal MRI scan would require further 
investigations including measurement of growth hormone-releasing hormone (GHRH) 
and imaging to identify ectopic growth hormone secretion. Since most tumours 
causing acromegaly are macroadenomas cure by transsphenoidal surgery is 




1.6.1 Molecular Forms of prolactin 
 
Human prolactin was first discovered in 1970 by Henry Friesen but was identified 40 
years earlier  in animals by Oscar Riddle (27). 
Prolactin is encoded by one gene on chromosome 6.  This gene consists of six 
exons and 4 introns. The molecular weight of mature biologically active prolactin is 23 
kDa and the protein consists of 199 amino acids. Other variants of prolactin include: 
‘big prolactin’ and ‘big-big prolactin’ (macroprolactin), it has high molecular mass (>150 
kDa) and it is complexes of 23 kDa prolactin and IgG autoantibodies, but it has no 
biological activity. Structurally prolactin similar to growth hormone and placental 
lactogen (28). 
 
1.6.2 Prolactin Receptor 
 
The prolactin receptor is encoded by the PRLR gene on chromosome 5.  It consists of 
about 10 axons and  is one of the haematopoietic cytokine receptor superfamily 
members. It has three extracellular domains, a transmembrane domain  and an 
intracellular signal-transducing domain (29). 
1.6.3 Regulation of prolactin secretions 
 
Prolactin is mainly produced from the anterior pituitary (lactotroph cells) but there is 
also extra pituitary production of prolactin (myometrium, 
breast, lymphocytes, leukocytes, and prostate) (30). 
The prolactin gene is regulated by transcription factor POU1F1. Thyrotropin-releasing 
hormone (TRH) enhances the release of prolactin whereas dopamine inhibits prolactin 
secretion. 
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In the absence of pregnancy, prolactin is tonically inhibited by dopamine, and 
the effect of dopamine overcomes the effect of TRH. In pregnancy, the high levels of 
estrogen stimulate prolactin release directly from the anterior pituitary. Suckling 
stimulates sensory nerves which carry a signal through the spinal cord to the arcuate 
nucleus to inhibit dopamine and increase the production of prolactin. An efferent  
signal from the nipple stimulates supraoptic and paraventricular nuclei to produce 
oxytocin to eject milk. Prolactin inhibits the release of GnRH causing amenorrhea 
during lactation (31) (32). 
1.6.4 Function of prolactin 
The main functions of prolactin in women are stimulation of milk secretion and 
enhancement of breast tissue growth in the presence of estrogen and progesterone. 
Prolactin activates the enzymes that are responsible for milk production, however, 
during pregnancy, lactogenesis is inhibited by the high level of estrogen and 
progesterone (33). 
In men, studies show that prolactin can increase the sensitivity of luteinizing hormone-
receptors in testes which results in maintaining the production of sperm (34). 
Prolactin may enhance myelin repair in the maternal central nervous system and it 
may also  have a role in regulating maternal behaviour (35). 
1.6.5 Causes of hyperprolactinemia 
In most laboratories, the upper limit of normal for serum prolactin is approximately 20 
ng/mL (20 mcg/L SI units). The measurement of prolactin is not affected by food, so it 
can be checked at any time of the day. 
Hyperprolactinemia may be divided into four types: physiological, functional, 
analytical, and pathological hyperprolactinemia. 
High levels of estrogen during pregnancy can cause a physiological increase in the 
prolactin level, usually in the range of  35 to 600 ng/mL (35 to 600 mcg/L SI units).  
During the postpartum period the level decreases gradually and by 6 weeks it returns 
to the normal value, even if the mother lactating (36). 
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Other causes of physiological hyperprolactinemia include nipple stimulation during 
breastfeeding, stress, physical exertion, hypoglycaemia, or sexual intercourse.  
Prolactin levels in these situations are typically very mild (37). 
Dopamine D2 receptor antagonists (antipsychotics) may raise serum prolactin usually 
into the  range of 25 to 100 ng/mL (25 to 100 mcg/L), however, risperidone may 
increases prolactin concentrations up to 200 ng/mL (200 mcg/L) (38). Several other 
drugs have been associated with hyperprolactinemia, for example, selective serotonin 
reuptake inhibitors (39), methyldopa(40) and verapamil (41). 
The most important pathological cause of hyperprolactinemia is hypothalamic-pituitary 
disease (HPD) that interferes with the secretion of dopamine (Stalk-Effect) and 
Lactotroph adenomas. The usual prolactin level in patients with HPD is not more than 
200 ng/mL (200 mcg/L SI units), whereas the prolactin level varies according to the 
size of lactotroph adenoma, and can vary from  mildly elevated up to several thousand 
fold elevated (42). 
Other causes of hyperprolactinemia include hypothyroidism, chest wall injury, use of 
estrogen, renal failure, macroprolactinemia and idiopathic. Mutations in the prolactin 
receptor gene can cause familial hyperprolactinemia (see table 2) (43). 
 
1.6.6 Clinical presentation of hyperprolactinemia  
 
The main consequence of hyperprolactinemia is secondary hypogonadism and the 
effect of hypogonadism on bone. High levels of prolactin cause inhibition of luteinizing 
hormone (LH), and follicle-stimulating hormone (FSH) secretion, through inhibition of 
the release of gonadotropin-releasing hormone (GnRH) (see table 3). 
Premenopausal women can present with amenorrhea or oligomenorrhea and this may 
be associated with galactorrhea but galactorrhea is often not present (42). In men, 
hyperprolactinemia is associated with impaired libido and impotence, infertility 
(oligospermia and decreased in volume), gynecomastia (rarely galactorrhea), 
decreased muscle mass and body hair (37). 
Prolactin within the normal range has a positive effect on bone formation, whereas a 
high prolactin level may increase bone resorption and inhibit bone formation. 
Premenopausal women with amenorrhea and hyperprolactinemia have low bone 
density compared with women with normal menses with or without hyperprolactinemia. 
In addition, men with hyperprolactinemia are at risk of metabolic bone disease. 
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Trabecular bone is affected earlier than cortical bone and the abnormal bone density 
can be improved when the hyperprolactinemia is corrected (44). 
Postmenopausal women with hyperprolactinemia due to a pituitary tumour usually 
come to clinical attention when the tumour becomes large enough to cause headaches 
or impaired vision or if it is detected as an incidental finding on magnetic resonance 
imaging (MRI). 
 
1.6.7 Prolactin Assays 
 
Clinical settings in which prolactin is commonly requested are menstrual irregularities 
(amenorrhea and oligomenorrhea), infertility, galactorrhoea, sexual dysfunction, 
gynaecomastia in men, suspected pituitary dysfunction, suspected pituitary mass 
lesion, before initiation of some antipsychotic medications (baseline) or  monitoring of 
prolactin levels in patients on antipsychotic medications 
Prolactin is currently measured by a two-site immunometric or sandwich principle 
which is more sensitive and specific. It uses two antibodies directed to different 
epitopes of the analyte: the first antibody (the ‘capture’ antibody) is immobilized onto 
a solid support and binds analyte in the sample; a second antibody (labelled antibody) 
binds to a different epitope on the analyte to form a sandwich complex, with the analyte 
bound to both the first and second antibodies. Any unbound labelled antibody is 
washed away before quantification of the generated signal. The dose-response curve 
generated in an immunometric assay is directly proportional to the analyte 
concentration (i.e. the signal increases progressively with the analyte concentration). 
Other molecules like growth hormone and placental lactogen may cross-react with the 
prolactin assay, however, using two antibodies directed to both prolactin epitopes can 
prevent the cross-reactive process. Heterophile antibodies can cause a  falsely 
elevated prolactin level, but adding blocking agent can prevent this interference(28) 
(45). 
Macroprolactin is a complex of prolactin and IgG with a mass of more than 150 
kilodaltons compared with 23 kDa for monomeric prolactin.  Macroprolactin is  
biologically inactive and is of no clinical consequence [46]. Therefore excluding 
macroprolactinemia is crucial as it prevents the  misinterpretation of results and can 
prevent unwanted further investigations. The best method to avoid misdiagnosis is to 
pre-treat the serum before the immunoassay with polyethylene glycol (PEG) to 
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precipitate macroprolactin(46). High-pressure liquid chromatography is another 
method that can be used for the separation of monomeric prolactin (47). 
1.6.8 Hook effect 
The Hook effect should be excluded particularly in presence of a macroadenoma and 
if the prolactin level is between 20 and 200 ng/mL (20 to 200 mcg/L SI units) 
It occurs in the setting of very high serum prolactin e.g., 5000 ng/mL (5000 mcg/L SI 
units) and is due to the elevated number of analyte molecules that bind to both the 
capture and detection antibodies, thereby preventing them from forming sandwich 
immune complexes. The result is an underestimation of the analyte concentration, 
while the actual analyte concentration is much higher (48). 
It can be overcome by serial sample dilution a 1:10, 1:100, or even a 1:1000 dilution, 
so that the true analyte concentration will fall within the analytical measurements range 
for the assay (49). 
1.7 Prolactinoma 
The cause of a prolactinoma is not fully known. The tumour has undergone somatic 
mutation and the tumour arises from the monoclonal line of lactotroph cells. Pituitary 
tumour transforming gene (PTTG) overexpression and mutation of a receptor of 
fibroblast growth factor 4 (FGF4) seem to play a role in pathogenesis. The tumour is 
sporadic  but may occur as part of familial syndromes, for example isolated familial 
prolactinoma, tumour and multiple endocrine neoplasia type 1 (MEN1) tumour(50). 
Anatomically, the most common sites involved by a prolactinoma is the lateral part of 
the anterior pituitary gland (28). 
Pituitary adenomas secreting prolactin (prolactinoma) account for approximately 30 to 
40 %% of all pituitary adenomas. It is more common in women than in men, especially 
between the ages of 20 and 40 years (51). However, in men the adenomas are usually 
larger(52). The prevalence of a prolactinoma is estimated to be 500 cases per million, 
the incidence is 27 cases per million per year, and 60% of microadenomas prevailing 
in women. Prolactin-secreting carcinomas are extremely rare (53). In addition, any 
tumour in or near the hypothalamus or pituitary interfering with the secretion of 
dopamine can cause hyperprolactinemia and may present as a prolactinoma (54). 
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The clinical manifestations of hyperprolactinemia in premenopausal women and men 
are mainly symptoms and signs of hypogonadism (hypogonadotropic hypogonadism). 
Postmenopausal women are already hypogonadal, so they only seek medical advice 
when the tumour becomes large enough to cause headaches or impair vision or is 
detected as an incidental seller mass by magnetic resonance imaging (MRI). 
Galactorrhoea is rare in this age group because of low estrogen levels. 
Prolactinomas are classified as a microprolactinoma (smaller than 10 mm), 
macroprolactinoma (larger than 10 mm), or a giant prolactinoma (larger than 40 mm). 
Prolactin levels secreted by lactotroph adenomas are usually correlate with adenoma 
size. Adenomas <1 cm in diameter are typically associated with serum prolactin 
values below 200 ng/mL (8.7 nmol/L), those 1 to 2 cm in diameter with values 
between 200 and 1000 ng/mL (8.7 to 43.48 nmol/L), and those greater than 2 cm in 
diameter with values above 1000 ng/mL (43.48 nmol/L) and as high as 
50,000 ng/mL (2173.91 nmol/L). There are exceptions to these rules, as occasional 
patients have a large macroadenoma and mild elevation in prolactin levels. In 
general, prolactin values more than 200 ng/mL usually indicate the presence of a 
lactotroph adenoma (55). 
The factors that lead to modest elevations of prolactin in patients with a 
macroadenoma are the hook effect, adenomas that are not well differentiated and if 
adenomas are largely cystic with only small portion producing prolactin. 
In all patients with hyperprolactinemia and after excluding other causes a MRI scan of 
the pituitary should be performed with any degree of hyperprolactinemia to look for a 
mass lesion in the hypothalamic-pituitary region (55). Other pituitary function should 
also be assessed, particularly in macroprolactinomas, especially growth hormone 
(GH) co-secretion should be excluded clinically and biochemically if necessary. Bone 
densitometry may be required. Patients with a macroadenoma need ophthalmological 
assessment, and a transthoracic echocardiogram should be considered before the 
initiation of dopamine agonist (56). 
A strong indication to treat a prolactinoma is existing or impending neurologic 
symptoms due to mass effect (visual disturbances or headache) with the goal being 
to reduce the size of adenoma. There is a 5% risk of a microadenoma enlarging over 
four to six years (57). Another indication for treatment is to restore e eugonadism, 
thereby preventing the adverse effect of hypogonadism on bone (premenopausal 
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women and men), as well as other symptoms due to hyperprolactinemia, such as 
galactorrhoea. Treatment options are medical, surgery, and radiotherapy (49). 
The first line of treatment is a dopamine agonist drug (DA).  These drugs are  indicated 
for patients with hyperprolactinemia of any cause, including lactotroph adenomas 
(prolactinomas) of all sizes because they decrease serum prolactin concentrations and 
decrease the size of most lactotroph adenomas in more than 90% of patients(58). 
Generally, DA have better results in normalising prolactin levels than tumour reduction, 
and the reduction of size is frequently based on prolactin levels (50). 
Cabergoline is the first choice because of its efficacy and favorable side-effect profile 
compared to bromocriptine(49). Resistance to bromocriptine is about 25 %%  and 
most (80 %%) can achieve normal prolactin concentrations with cabergoline therapy.  
Resistance to cabergoline is approximately 10 %% (59). 
In the first two to three weeks of therapy with a DA the serum prolactin level starts to 
decrease (60). The decrease in adenoma size can occur within six weeks to six 
months after initiation of treatment (61) and vision usually begins to improve within 
days after starting treatment (62). There is a recovery of menses and fertility in women 
and of testosterone secretion, sperm count, and erectile function in men. The rest of 
the pituitary function (thyroid and adrenal axis) may also have a return to normal (63). 
The common side effects of DAs are nausea, postural hypotension, and mental 
fogginess, less common side effects include nasal stuffiness, depression, Raynaud 
phenomenon, alcohol intolerance, and constipation. The side effects can be avoided 
by titrating the DA gradually, and by giving it with food or at bedtime. Cabergoline and 
pergolide have been associated with valvular heart disease, also bromocriptine may 
lead to subclinical valvular fibrosis(64), but most studies showed that the low doses of 
cabergoline usually used to treat hyperprolactinemia are not associated with excess 
risk (65). Impulse control disorders (such as hypersexuality and compulsive gambling, 
shopping, or eating) are one of DAs adverse effects that have recently been described 
(66). 
For a microadenoma, the Endocrine Society clinical guidelines suggest to reduce the 
dose gradually, as long as the prolactin level remains within the normal range, and if 
the prolactin levels remains normal for two years while the patient is taking a low dose 
(e.g., 0.25 mg twice a week) of cabergoline and there is no evidence of an adenoma 
on MRI for the same period the suggestion is a trial of discontinuation of the drug. The 
same approach can be applied to a macroadenoma as long as there is no adenoma 
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detectable by MRI for at least two years, otherwise discontinuation should 
probably not be considered. Follow up is clinical and by measurement of prolactin after 
three months and annually thereafter.  If the prolactin increases substantially (e.g., to 
>100 ng/mL), particularly in a patient who had a macroadenoma, a MRI scan should 
be requested and treatment with a  DA should be resumed to normalize the prolactin 
(67) (49). 
Dopamine agonist resistance was defined as a failure to achieve normoprolactinemia 
or failure to enable a 50% reduction of hyperprolactinemia under maximally tolerated 
doses of DA (≥ 15 mg of bromocriptine/day, ≥ 2.0 mg of cabergoline 2 times per week) 
for at least 3-6 months, and the lack of a 30% or more reduction in tumour diameter in 
the case of a macroprolactinoma(68)(69). Options available for these situations are 
transsphenoidal surgery or radiotherapy. Other indications for surgery are intolerable 
side effects of DA, patient preference, and a woman with a macroprolactinoma (e.g., 
>3 cm)  wishes to become pregnant, to attempt to avoid dopamine agonist treatment 
during pregnancy(70). Overall transsphenoidal surgery normalizes prolactin levels in 
80 %% in cystic prolactinomas, and 84.8 %% in microprolactinomas and the 
recurrence rate is 18.7 %, although only 7.1 % in microadenomas (71). 
Because most prolactinomas respond well to DAs, radiation therapy is only usually 
used after debulking surgery to avoid regrowth of any residual tumour and there is no 
role to use radiation in patients with microadenomas. The effect of radiation (single 
dose or multiple fraction) on the aggressive lactotroph adenoma is less well-known 
compare to other types of pituitary adenomas (72) (73). 
The largest study in Africa on prolactinomas is found in the literature as a thesis and 
has not yet been published and undergone peer review.  Beyene et al (2021) report 
on 69 patients with a prolactinoma in Ethiopia (74).  The majority of patients were 
female (76.8%) and the majority (79.7%) were found to have a macroprolactinoma.  
Surgery for mass effect was only required in 11 patients and 85.5% had a good clinical 
response to treatment with carbergoline.  Three small studies from Cameroon (n=25), 
Cameroon (n=36 cases) and Ethiopia (n=20 cases) all showed a good response to 
treatment with carbergoline with few patients requiring surgery (75)(76)(77).  A study 
form Nigeria included 76 patients with infertility secondary to hyperprolactinaemia and 
found that at the end of 8 weeks of treatment with cabergoline 98.7% had their serum 
prolactin levels restored to normal (78). 
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1.7.1 Prolactinomas in pregnancy 
 
During pregnancy there is enlargement of the  pituitary gland due to lactotroph 
hyperplasia (79). Hyperprolactinemia suppresses gonadotropin-releasing hormone 
(GNRH) through suppression of kisspeptin which causes decreases of luteinizing 
hormone (LH) pulse amplitude and frequency. Hyperprolactinemia  inhibits 
progesterone production and  directly suppresses estrogen secretion from ovaries 
(80). The short-luteal phase is the earliest evidence of a cycle abnormality caused by 
hyperprolactinemia in women and most women with hyperprolactinemia become 
anovulatory with resultant amenorrhea and infertility. Treatment of hyperprolactinemia 
may restore the normal menstrual cycle and women with a prolactinoma can get 
pregnant. 
During pregnancy in a woman with prolactinoma, two important issues arise, the effect 
of DAs on fetal development and an increase in adenoma size because of the high 
levels of estrogen. The risk of enlargement for a microprolactinoma is low, while the 
risk for a macroprolactinoma is substantially higher. The safety of DAs during 
pregnancy has not been established and the recommendations are to stop it during 
pregnancy. Human studies showed that bromocriptine crosses the placenta and 
cabergoline has been shown to do so in animal studies but no data is available in 
humans (81). 
There is sparse data on the use of bromocriptine and cabergoline during pregnancy, 
however, available data shows the risk of congenital malformations did not appear to 
be higher in pregnant women taking a DA than non-exposed pregnancies (82) (83). 
DAs should be restarted in women with evidence of tumour growth throughout the 
remainder of the pregnancy, and transsphenoidal surgery may be considered in the 
second trimester if the condition deteriorates or does not respond to DA. 
Adenoma size doesn’t increase during lactation but the prolactin level is usually 
increased (84) and DAs impair lactation. Breastfeeding is not contraindicated in 
women with a macroadenoma or microadenoma that is of stable size, but it is 
contraindicated for patients who have visual field impairment because they should be 
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Background: Prolactin-secreting tumours(prolactinomas) are the commonest type of 
pituitary tumour, accounting for approximately 30 to 40 %% of all pituitary adenomas. 
Although there is ample epidemiologic and clinic data from Industrialized countries 
there remains sparse data from Africa. Specifically, the clinical presentation, and 
hormonal deficiencies and treatment outcomes in the South Africa have not been 
described. 
Methods: A retrospective study of all patients with a diagnosis of prolactinoma 
attending the Endocrine and Pituitary Clinics at Groote Schuur Hospital over a 12-
month period, between March 2019-March 2020. Patients folders were reviewed to 
retrieve the following information: demographic data, clinical presentation, clinical 
signs, prolactinoma phenotype, hormonal deficiencies, treatment modalities and 
clinical outcomes. 
Results: Over 12-month period 52 patients were included in this study, females 73% 
(n=38), mean age of all participants was 46.1 ± 14.6 years.  A macroprolactinoma was 
present in 67.3% (n=35) of patients and 32.7% (n=17) of patients had a 
microprolactinoma. In the macroprolactinoma group: the common presenting 
symptoms were headache 88.6% (n=33), altered vision 40% (n=14) and, in females, 
amenorrhea  63.6% (n=14) but a cranial nerve palsy 17.1% (n=6) and  apoplexy 5.7% 
(n=2) were uncommon. In the microprolactinoma group the common presenting 
symptoms included amenorrhea 75% (n=12), galactorrhoea 70.6% (n=12), headache 
64.7% (n=11). On presentation the majority of patients with a macroadenoma had at 
least one hormonal abnormality with hypogonadism 73.1% (n=19) being most 
common, followed by hypothyroidism 53.8% (n=14) and hypoadrenalism 30% (n=8). 
Over 50% of patients with a giant adenoma had panhypopituitarism with 
hypogonadism in 100%, hypothyroidism in 77.8% (n=7) and hypoadrenalism in 66.7% 
(n=6). Hormonal deficiencies in the microadenoma group on presentation included 
hypogonadism 64.7% (n=11), hypothyroidism 35.3 (n=6) and one patient had 
hypoadrenalism. All patients received medical treatment, however, in the 
macroadenoma group 4 patients required surgical debulking of the tumour, 3 patients 
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required a ventriculo-peritoneal (VP) shunt for hydrocephalus and 2 patients required 
radiation. 
After a median follow-up of 46.5 months, the median prolactin level decreased from 
322.5 ug/l (94.0-4282.0) at presentation to 17.5 ug/l (8.6-82.5) at follow-up.  In parallel 
there was a reduction of 12.2 ±9.7 mm in tumour size after a mean of 59.8 ±53.3 
months. 
There was resolution of hypogonadism in 56.4% (n=22), of hypothyroidism in 2.7% 
(n=2) and hypoadrenalism only resolved in 1 patient. 
Conclusions: Most patients with a prolactinoma are symptomatic and have at least 
one hormone deficiency on presentation.  With medical management most patients 
experienced a reduction in prolactin levels and tumour size. This was associated with 
the resolution of hypogonadism in the majority, however, hypothyroidism and 
hypoadrenalism are unlikely to resolve despite a reduction in tumour size. 
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2.2 Introduction  
 
Prolactin-secreting tumours (prolactinomas) are the commonest type of pituitary 
tumour, is associated with significant hormonal disturbances and may cause 
neurological complications. The burden and management of prolactinoma in Africa 
have not been well documented. Although there is ample epidemiologic and clinic data 
from Industrialized countries there remains sparse data from Africa. Specifically, the 
clinical presentation, and hormonal deficiencies and treatment outcomes in the South 
Africa have not been described. This is first description of patients with a prolactinoma 
being managed in sub-Saharan Africa. The current study is expected to increase 
awareness of management and outcome of this disease. 
 
2.3 Aims & Objectives 
Aim  
The aim of this study was to assess all patients with a prolactinoma attending the 
Pituitary and General Endocrine Clinics at Groote Schuur Hospital. These findings will 
confirm the effectiveness of the current treatment strategy and may inform changes to 
management for future patients managed for a prolactinoma at Groote Schuur 
Hospital.   
Objective 1: To describe the spectrum of prolactinomas. 
Objective 2: To describe the phenotype and the clinical presentation of a patients 
diagnosed with a prolactinoma. 
Objective 3: To describe the treatment of patients diagnosed with a prolactinoma and 
their response to management. 
2.4 Methods 
 
2.4.1 Study design:  
 
Retrospective folder review 
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2.4.2 Setting: 
Pituitary and General Endocrine Clinics at Groote Schuur Hospital (GSH). GSH is a 
tertiary hospital in Cape Town, SA. 
2.4.3 Study population: 
All patients between March 2019- March 2020 attending the Pituitary and General 
endocrine Clinics at Groote Schuur Hospital with a diagnosis of a prolactinoma. 
2.4.4 Procedures: 
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2.4.5 Data safety, analysis, and monitoring: 
The data were collected by clinicians working in the Pituitary and General endocrine 
Clinics at GSH and processed in an excel spreadsheet. All patient data was 
anonymized  identification number. No personal/identifying details will be utilized in 
the analysis and subsequent publications. The patient’s data will be confidential and 
will be accessible to researchers only. This data will be updated regularly as new 
information is collected. 
2.4.6 Statistical analysis 
The data were analysed using Stata 16.1 and descriptive statistics were performed. 
We described the baseline characteristics of the study cohort and grouped them by 
according to the size of macroadenoma (giant, macro- and micro-adenoma). We also 
described the change in tumour size, and hormonal status of the participants during 
the study period. Proportions and percentages for each variable were calculated and 
presented in tables and figures. No comparative statistical analysis was performed 
owing to low sample size and inadequate power.  
2.4.7 Ethical aspects: 
Ethics approval was obtained from the UCT - Faculty of Health Sciences Human 
Research Ethics Committee (REC-210208-007). Also, application for renewal of 
ethical approval was requested, see appendix 2. In addition, GSH research committee 
gave permission to review the relevant folders on the premises. Since it is a 
retrospective study and data were retrieved from patients’ folders, individual patient 
consent was not required. 
Before the study commenced and data was collected, research ethics approval for 
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the project was received from the Faculty of Health Sciences Human Research 
Committee. Approval number Ref no: 170/2019. 
(Ethics approval for the study – see Appendix 2) 
The most important ethical consideration in this study was patient confidentiality.  The 
data was collected through a folder review. The retrospective information was 
confidentially collected by a review of the information already present within the 
patients’ folders. The patients’ clinic visits and routine laboratory investigations were 
not altered and the study followed the best clinical practice guidelines.  As this was a 
retrospective folder review, informed consent was waived.  Patient confidentiality was 
maintained by storing all of the information from the patients’ folders, under the unique 
folder number in the registry. This registry was only accessible via a unique coded 
password, known only to the investigators. The data was stored on a password locked 




Between 15 March 2019 and 30 March 2020, 52 patients with prolactinomas were 
identified and included in this study. A 1-year period was selected as most patients 
with a prolactinoma are seen in our clinic each year. The median age at diagnosis was 
36.5 years (29.0-46.0) and the majority of patients were female, 73.1% (n=38) (Table 
4).  The most common presenting symptoms were headache [80.8% (n=15), 
amenorrhea in females [68.4% (n=26), galactorrhoea [42.3% (n=22) and a visual field 
defect [38.5% (n=20)].   
Clinical presentation by size category of tumour 
  A macroprolactinoma was present in 67.3% (n=35) of patients with a median age at 
diagnosis of 36.0 years (27.0-49.0), whereas 32.7% (n=17) of patients had a 
microprolactinoma with a median age at diagnosis of 38.0 years (30.0-44.0) (Table 4).  
Patients with a macroprolactinoma were more likely to be female [62.9% (n=22)] and 
were more likely to present with a headache [88.6% (n=31)], a visual field defect 
[51.4% (n=18)], altered vision [40.0% (n=14)] and galactorrhoea 28.6% (n=10).  
Patients with a microprolactinoma were also more likely to be female [94.1% (n=16)] 
and to present with galactorrhea [70.6% (n=12) and/or headache [64.7% (n=11)]. 
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Amenorrhea was present in 36.8% (n=14) of females with a macroprolactinoma and 
in 31.6% (n=12) of females with a microprolactinoma. Cranial nerve palsies 17.1% 
(n=6) and pituitary apoplexy (n=2) were uncommon in both groups.  In the subset of 
patients with a giant adenoma, the majority of patients were male [55.6% (n=5)] with 
a median age of 34.0 years (28.0-38.0) (Table 5). The most common symptoms on 
presentation were headache [100% (n=9)] and altered vision 44.4% (n=4).       
Clinical presentation by sex 
The majority of males were diagnosed with a macroprolactinoma [57.1% (n=8)] or a 
giant prolactinoma [35.7% (n=5)] whereas 42.1% (n=16) of females presented with a 
microprolactinoma, 47.4% (n=18) presented with a macroprolactinoma and 10.5% 
(n=4) presented with a giant prolactinoma (Table 6). Males were more likely than 
females to present with a visual field defect [64.3% (n=9) vs 28.9% (n=28.9%, 
p=0.020] and a cranial nerve palsy [28.6% (n=4) vs 5.3% (n=2), p=0.020] whereas 
females were more likely to present with apoplexy [5.3% (n=2) vs 0.0% (n=0), 
p=0.009]. There was no significant difference between females and males for altered 
vision (p=0.18), headache (p=0.18) or galactorrhea (p=0.064) 
Tumour size and hormonal abnormalities at diagnosis 
The mean tumour size of a microprolactinoma was 6.1 ± 2.3 mm (n=12, five 
microadenomas reported as “evidence of microadenoma and bulky pituitary” without 
an actual tumour size provided ),  a macroprolactinoma was 21.4 ± 8.8 mm (n=25) and 
of a giant prolactinoma was 51.6 ± 6.4 mm (n=9) (Table 7). At diagnosis, males had 
larger tumours than females [34.3 ± 17.7 mm vs 18.5 ± 14.5 mm, p=0.003) (Table 8).   
Median serum prolactin levels in patients with a microprolactinoma, 
macroprolactinoma or a giant prolactinoma were 97.0 ug/l (72.0-142.0), 434.5 ug/l 
(133.0-282.0) and 10 986.0 ug/l (6278.0-14051.0), respectively (Table 7).  Males had 
higher serum prolactin levels than females [299.7 ug/l (412.0-4671.0) vs 145.5 ug/l 
(73.0-726.0), p=0.013) (Table 8).  The majority of patients had at least one hormonal 
abnormality with hypogonadism 73.1% (n=19) being most common, followed by 
hypothyroidism 53.8% (n=14) and hypoadrenalism 30% (n=8).   
Hypogonadism was present in 64.7% (n=11) with a microprolactinoma, 73.1 % (n=11) 
with a macroprolactinoma and in 100% (n=9) with a giant prolactinoma (Figure 1 A).  
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Hypothyroidism was present in 35.3% (n=6) with a microprolactinoma, 53.8 % (n=14) 
with a macroprolactinoma and in 77.8 % (n=7) with a giant prolactinoma (Figure 2 A).  
Hypoadrenalism was present in 5.9% (n=1) with a microprolactinoma, 30.8 % (n=8) 
with a macroprolactinoma and in 66.7% (n=6) with a giant prolactinoma (Figure 3 A).  
Males were more likely than females to have hypoadrenalism [71.4% (n=10) vs 13.2% 
(n=5), p<0.001], however, there was no significant difference between males and 
females having hypogonadism or hypothyroidism at diagnosis (Table 8)          
Treatment of patients with a prolactinoma 
All patients were treated medically [cabergoline 88.46% (n=46) and bromocriptine 
11.54% (n=6)], however, 4 patients with a macroadenoma required surgical debulking 
of the tumour (3 trans-sphenoidal, 1 craniotomy), 3 patients with a giant adenoma 
required a ventriculo-peritoneal (VP) shunt for hydrocephalus and 2 patients required 
radiation (1 with a giant adenoma, 1 with a macroadenoma after surgical debulking of 
the tumour).  
Serum prolactin level and tumour size after treatment 
After a median follow-up of 46.5 months there was significant reduction in the serum 
prolactin level. In the  macroadenoma group the median prolactin level decreased from  
434.5 ug/l (133.0-4282.0) at presentation to 13.2 ug/l (8.2-27.0) at follow-up, whilst in 
the giant adenoma group the median prolactin level decreased from 10986.0 ug/l 
(6278.0-14051.0) at presentation to 411.0 ug/l (15.0-1073.0) at follow-up.  In the 
microadenoma group the median prolactin level decreased from 97.0 ug/l (72.0-142.0) 
at presentation to 19.0 ug/l (7.0-80.0) at follow-up. There was no significant difference 
in prolactin levels between males and females after treatment (p=0.27) (Table 8).   
In parallel with the reduction in prolactin level there was a reduction in tumour size.  In 
the giant adenoma group, after a mean of 30.5 ± 23.6 months, there was a 19.5 ± 11.8 
mm reduction in size, in the macroadenoma group, after a mean of 74.8 ± 62.2 months, 
there was a 11.2 ± 7.8 mm reduction in size and in the microadenoma group, after a 
mean of 52.6 ± 33.5 months, there was a 4.0 ± 3.4 mm reduction in size. There was a 
greater reduction in tumour size in the males when compared to the females [-18.6 ± 
12.6 mm vs -9.1 ± 6.3 mm, p=0.009] (Table 7). Only 5 patients with a microadenoma 
had a follow-up MRI scan, and in 3 of these patients no residual tumour was visible.  
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However, 18 patients with a macroadenoma had a repeat MRI scan and in 3 of these 
patients  there was a normal pituitary gland and in 4 of these patients there was an 
empty Sella (Table 7). Only 1 patient with a microadenoma had an increase (of 1 mm) 
in size of their tumour and 2 patients with a macroadenoma their tumour size remained 
the same size despite a decrease in their serum prolactin level (Table 7).   
Hormonal abnormalities after treatment 
In the giant adenoma group, 1 patient developed new hypothyroidism after treatment 
that included a VP shunt, in 2 patients hypogonadism resolved, 1 patient developed 
new onset hypoadrenalism and in 1 patient the hypoadrenalism resolved.  In the 
macroadenoma group, 2 patients developed new hypothyroidism after treatment, in 1 
patient the hypothyroidism resolved and in 8 patients hypogonadism resolved.   In the 
microadenoma group, in 3 patients the hypothyroidism resolved, in 12 patients the 
hypogonadism resolved and in 1 patient the hypoadrenalism resolved.  
Hypogonadism was present in 0.0% (n=17) with a microprolactinoma, 38.5 % (n=10) 
with a macroprolactinoma and in 77.8% (n=7) with a giant prolactinoma (Figure 1 B). 
Hypothyroidism was present in 23.5% (n=4) with a microprolactinoma, 50.0% (n=13) 
with a macroprolactinoma and in 88.9% (n=8) with a giant prolactinoma (Figure 2 B).  
Hypoadrenalism was present in 5.9% (n=1) with a microprolactinoma, 26.9% (n=7) 
with a macroprolactinoma and in 66.7% (n=6) with a giant prolactinoma (Figure 3 A).  
Males were more likely than females to have hypogonadism [78.6% (n=11) vs 15.8% 
(n=6), p<0.001], hypothyroidism [71.4% (n=10) vs 13.2% (n=5), p=0.011] and 
hypoadrenalism [64.3% (n=9) vs 13.2% (n=5), p<0.001]. Over a mean time of 46.5 
months the prolactin level reduced from 2997.0 (412.0-4671.0) ug/l at presentation in 
males to 12.6 (4.0-27.0) ug/l and from 145.5 (73.0-726.0) ug/l to 19.5 ug/l (10.2-85.0) 
in females. After a mean time of 59.8 ± 53.3 months of follow up, MRI showed a mean 
reduction in tumour size of 18.6 ±12.6 mm in males and 9.1 ± 6.3 mm in females (Table 
2). 
2.6 Discussion 
This study is one of the largest studies from Africa and the 1st study from South Africa 
to describe a cohort of patients diagnosed with a prolactinoma. The main aim of this 
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study was to describe the presentation and clinical outcomes of patients attending the 
Endocrine Clinic with a diagnosis of a prolactinoma. The results of this study were 
similar to Beyene et al (2021) in that the majority of the patients were female (Abdalla 
73.1% vs Beyene 76.8%), the majority had a macroprolactinoma (Abdalla 67.2% vs 
Beyene 79.7%), surgery was required in few (Abdalla 13.5% vs Beyene 11.6%) and 
the majority had a good clinical response to dopamine agonists (Abdalla 90.3% vs 
Beyene 85.5%).  The preponderance of females in this study is consistent with the 
literature. The reason for the predominance of females in studies is attributed to the 
nature of the disease presentation, usually resulting in women seeking medical 
attention for infertility and/or a menstrual disturbance. The absence of these symptoms 
may underdiagnose early disease in males and may also result in them presenting 
later in the course of their disease only when they develop symptoms of mass effect.  
Indeed, in this study we have found that males were more likely to have a 
macroprolactinoma and a giant prolactinoma with only one male patient having a 
microprolactinoma. In addition, males were more likely to present with symptoms of 
mass effects such as headache and visual disturbances.  According to the 2017 World 
Health Organization classification of pituitary adenomas, the more aggressive and 
resistant densely granulated prolactinomas are likely to be found in males (1). Also, 
multiple studies have also shown that the prevalence of macroprolactinomas is more 
common in males compared to females (2) (3) (4).  
Interestingly, we found patients with a microprolactinoma were more likely to present 
with galactorrhea in comparison with patients in the macroprolactinoma and giant 
prolactinoma groups, despite the prolactin level in the latter groups being significantly 
higher.  This is difficult to explain.  Some macroprolactinomas may have higher levels 
of macroprolactin rather than monomeric prolactin, however, in our institution, 
macroprolactinemia is often excluded when an elevated prolactin level is identified. 
Aisaka et al (2018) demonstrated that the presence of macroprolactin was a significant 
factor in reducing the onset of galactorrhea (5).  
Notably, headache was the most common symptom among all groups and more 
common in patients with a macroprolactinoma.  The high prevalence of headache in 
patients with a microprolactinoma is surprising given the small size of most 
microprolactinomas, considered unlikely to cause any significant mass effect. A few 
reports have found that patients with a microprolactinoma may present with severe 
headaches, whereas the patients with macroprolactinoma may not have headaches 
 40 
and may present with visual symptoms and/or hormonal deficiencies. The functionality 
and biochemical activity of a microprolactinoma may explain the mechanism of 
headache in patients having small size tumours. Also, the alterations in the dopamine–
prolactin axis may play a role in the pathogenesis of headaches, this hypothesis is 
supported by the fact that usually, patients with prolactinomas respond well and the 
intensity of the headache improves after commencement of treatment with a dopamine 
agonist and before regression of adenoma size (6) (7) (8). 
Apoplexy was rare in this cohort with only two patients presenting with apoplexy from 
the macroadenoma and giant adenoma groups. In a large retrospective clinic 
population study, including 368 patients with a prolactinoma, the overall prevalence of 
pituitary hemorrhage in patients with a prolactinoma was 6.8% and was significantly 
higher in patients with macroadenomas 20.3% versus 3.1% in patients with a 
microadenoma (9) (10) (11). 
Interestingly, one patient with a giant prolactinoma presented with epistaxis. In this 
patient the prolactin level was very high, and an MRI of the pituitary gland showed a 
large suprasellar lesion extending into the nasopharynx. The patient responded well 
to treatment with cabergoline and the tumour regressed in the size without requiring 
surgical intervention. Epistaxis is a rare presenting symptom in patients with a pituitary 
adenoma. It has been attributed to infrasellar extension of the tumour into the 
nasopharynx or rupture of an internal carotid artery aneurysm embedded within a large 
prolactinoma or an ectopic pituitary adenoma (12) (13) (14).  
Medical management with a dopamine agonist is the primary treatment of a 
prolactinoma. All patients in this study received medical treatment with only a few 
requiring some form of surgical intervention. or radiotherapy. The main indications for 
surgery were neurological deficit including visual loss, apoplexy, or resistance to 
medical treatment (cystic prolactinoma). No patient developed dopamine agonist 
intolerance. The outcome of hormonal status, tumour size, and improvement of vision 
were better in patients who received medical treatment versus those who received 
medical and underwent surgery (15).  
All patients experienced a decrease in prolactin level on medical treatment and, in 
parallel with this, most patients experienced a reduction in tumour size. In most 
patients the prolactin level is thought to be an accurate predictor of tumour size (16).  
Only 2 patients in our cohort experienced a marginal increase in tumour size despite 
a reduction in the serum level of prolactin (17).   
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Hypogonadism and hypothyroidism resolved on treatment to various degrees in all 
patients, however, hypoadrenalism did not resolve significantly after treatment in any 
patient. In addition, hormone deficiencies in patients with a giant prolactinoma were 
least likely to resolve on treatment. Male patients were more likely to present with a 
hormonal deficiency, most likely explained by the larger size of their tumours on 
presentation. All patients who received radiotherapy developed panhypopituitarism. A 
reduction in the level of prolactin and the reduction in tumour size achieved after 
treatment with a dopamine agonist often results in the improvement of various 
hormone deficiencies. 
In a prospective study that assessed the gender response to cabergoline, after 5 years 
of treatment menses had resumed in 82% of women and libido had improved in 57% 
of men. Studies have also shown that hypogonadotropic hypogonadism was 
successfully treated in 90% of the patients who were treated with Cabergoline and in 
70–80% when treated with bromocriptine (18) (19). 
 A systematic review and meta-analysis that included 736 men treated medically 
mostly with cabergoline no difference in the success rate in treating 
hyperprolactinemia due to microprolactinoma or macroprolactinoma(20). Another 
study included 51 patients followed for 24 months treated with cabergoline describe 
the same conclusion (21). In contrast, a macroprolactinoma may cause permanent 
damage to pituitary cells due to mechanical destruction, a surgical procedure, or 
radiation and hypogonadism may become irreversible (18) (22).  
 
In this cohort there were four adolescent patients, age 17-18 years at presentation, 
three females and one male, two of them had a giant prolactinoma, one had a 
macroprolactinoma and one had a microprolactinoma. The patient who presented with 
a microprolactinoma had no hormonal deficiency on presentation as well as after 
treatment, whereas the patient with macroprolactinoma had only hypothyroidism at the 
time of the diagnosis and the pituitary function became normal during the period of the 
follow-up. The giant macroadenoma patients, one of them presented with 
panhypopituitarism which persisted after treatment, the other patient presented with 
hypogonadism and hypothyroidism and developed panhypopituitarism during follow-
up.  All were treated medically with a dopamine agonist. On follow-up, periods the MRI 
normalize in two patients (the microprolactinoma and the macroprolactinoma patients) 
as well as the prolactin level. A prolactinoma is rare in adolescents but has a significant 
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impact on growth and development. Similar to adults, the first-line treatment is a 
dopamine agonist and the indications of surgical intervention and radiation therapy are 
also the same, but the long-term prognosis and consequence of the disease is not well 
known (23) (24). 
This study has few limitations. The main limitation is that it is a cross-sectional study 
so only associations can be shown, and causation cannot be implied.  
The strengths of this study reside in it being the first description of patients with a 
prolactinoma being managed in sub-Saharan Africa.  It represents real-world local 
clinical data that can now be used to design long-term prospective studies to better 
guide investigation and management of these patients.  The median length of follow-
up of 5 years allows for adequate comment on treatment success with respect to 
serum prolactin levels, reduction in tumour size and resolution of hormonal 
deficiencies.   
2.7 Conclusion 
Prolactinomas were more common among young females, particularly a 
microprolactinoma. It is most commonly associated with a headache, sexual 
dysfunction and a hormone deficiency. With medical management most patients 
experienced a reduction in prolactin levels and a reduction in tumour size.  This was 
associated with the resolution of hypogonadism in the majority, however, 
hypothyroidism and hypoadrenalism are unlikely to resolve in the majority irrespective 
of tumour size. 
Future research might include increasing the number of cases and assessing factors 
that predict remission on medical treatment so that medical treatment can be 
withdrawn timeously thereby decreasing the costs associated with long-term 
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Pituitary cell type Hormone Disease 
Lactotroph Prolactin Prolactinoma 
Somatotroph Growth Hormone Acromegaly 






Thyrotroph Thyroid Stimulating 
Hormone 
TSH-secreting Tumor 




Physiologic Pharmacologic Pathologic 
   
Lactation & pregnancy Antipsychotics, first 
generation  
Prolactinoma 
Stress  Antipsychotic, second 
generation 
Hypophysial stalk lesion 
(stalk effect) 
Exercise Antidepressants, cyclic  Hypothyroidism 
Sleep Antidepressants SSRI  Chronic renal failure 
Seizures Antihypertensives 
Methyldopa Verapamil  
Sever liver failure 






Neurological symptoms Hormonal deficiency 
Headache Hypogonadism (amenorrhea, erectile 
dysfunction, loss of libido, infertility) 
Visual field defect Growth hormone deficiency 
Loss of vision Hypothyroidism 
Pituitary apoplexy Hypercortisolism 
Cerebrospinal fluid rhinorrhea Galactorrhea 





Variable Total Macroprolactinoma Microprolactinoma 
N=52 N=35 N=17 
Age at diagnosis 36.5 (29.0-46.0) 36.0 (27.0-49.0) 38.0 (30.0-44.0) 
Female sex 38 (73.1%) 22 (62.9%) 16 (94.1%) 
Apoplexy 2 (3.8%) 2 (5.7%) 0 (0.0%) 
Altered Vision 15 (28.8%) 14 (40.0%) 1 (5.9%) 
Headache 42 (80.8%) 31 (88.6%) 11 (64.7%) 
Field defect 20 (38.5%) 18 (51.4%) 2 (11.8%) 
CN palsy 6 (11.5%) 6 (17.1%) 0 (0.0%) 
Galactorrhea 22 (42.3%) 10 (28.6%) 12 (70.6%) 
Amenorrhea* 26 (68.4%) 14 (36.8%) 12 (31.6%) 
* only females included so n=38
Table 4: Baseline characteristics and presentation of patients with a prolactinoma 
by size of the prolactinoma 
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Total Giant Adenoma Macroadenoma Microadenoma 
N=52 N=9 N=26 N=17 
Age at diagnosis 36.5 (29.0-46.0) 34.0 (28.0-38.0) 38.5 (27.0-52.0) 38.0 (30.0-44.0) 
Female sex 38 (73.1%) 4 (44.4%) 18 (69.2%) 16 (94.1%) 
Apoplexy 2 (3.8%) 1 (11.1%) 1 (3.8%) 0 (0.0%) 
Altered Vision 15 (28.8%) 4 (44.4%) 10 (38.5%) 1 (5.9%) 
Visual field defect 20.8 (38.5%) 8 (88.9%) 10 (38.5%) 2 (11.8%) 
Headache 42 (80.8%) 9 (100.0%) 22 (84.6%) 11 (64.7%) 
CN palsy 6 (11.5%) 3 (33.3%) 3 (11.5%) 0 (0.0%) 
Galactorrhea 22 (42.3%) 2 (22.2%) 8 (30.8%) 12 (70.6%) 
Amenorrhea* 26 (68.4%) 2 (50.0%) 12 (66.7%) 12 (75.0%) 
Table 5: Clinical presentations, and managements at diagnosis and after treatment in the various 





























Total Female Male p-value 
 
N=52 N=38 N=14 
 
Diagnosis     
Age  36.5 (29.0-46.0) 36.0 (27.0-44.0) 37.0 (31.0-59.0) 0.39 
Classification     
   Giant Prolactinoma 9 (17.3%) 4 (10.5%) 5 (35.7%) 0.021 
   Macroprolactinoma 26 (50.0%) 18 (47.4%) 8 (57.1%)  
   Microprolactinoma 17 (32.7%) 16 (42.1%) 1 (7.1%)  
     
Apoplexy 2 (3.8%) 2 (5.3%) 0 (0.0%) 0.009 
Altered Vision 15 (28.8%) 9 (23.7%) 6 (42.9%) 0.18 
Headache 42 (80.8%) 31 (81.6%) 11 (78.6%) 0.18 
Field defect 20 (38.5%) 11 (28.9%) 9 (64.3%) 0.020 
CN palsy 6 (11.5%) 2 (5.3%) 4 (28.6%) 0.020 
Galactorrhea 22 (42.3%) 19 (50.0%) 3 (21.4%) 0.064 
 
 
Table 6: Clinical presentation by sex  
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Table 7: Serum prolactin level and tumor size at diagnosis and after treatment by size category of 
the prolactinoma  
Total Giant Adenoma Macroadenoma Microadenoma 




















At diagnosis N=46 N=9 N=25 N=12 
Tumour size 23.39(17.0) 51.6(6.4) 21.4(8.8) 6.1(2.3) 
After treatment N=31 N=8 N=18 N=5 
Tumour size change (mm) -12.2(9.7) -19.5(11.8) -11.2(7.8) -4.0(3.4)
Change in size* 
 Decreased 28 (90.3%) 8 (100%) 16 (88.9%) 4 (80%) 
 Increased 1 (3.2%) 0 (0.0%) 0 (0.0%) 1 (20.0%) 
 Not changed 2 (6.5%) 0 (0.0%) 2 (11.1%) 0 (0.0%) 
Follow up (months) 59.8 (53.3) 30.5 (23.6) 74.8 (62.2) 52.6 (33.5) 
Size classification 
Empty Sella 4 (12.9%) 0 (0.0%) 4 (22.2%) 0 (0.0%) 
Macroadenoma 18 (58.1%) 8 (100.0%) 9 (50.0%) 1 (20.0%) 
Microadenoma 3 (9.7%) 0 (0.0%) 2 (11.1%) 1 (20.0%) 




Total Female Male p-value
N=52 N=38 N=14 
Diagnosis 
Tumour size (mm) 23.3 (17.0) 18.5 (14.5) 34.3 (17.7) 0.003 
Hypothyroidism 27 (51.9%) 18 (47.4%) 9 (64.3%) 0.28 
Hypogonadism 39 (75.0%) 26 (68.4%) 13 (92.9%) 0.071 









Tumour Size Change -12.2 (9.7) -9.1 (6.3) -18.6 (12.6) 0.009 
Hypothyroidism 25 (48.1%) 15 (39.5%) 10 (71.4%) 0.041 
Hypogonadism 17 (32.7%) 6 (15.8%) 11 (78.6%) <0.001 
Hypoadrenalism 14 (26.9%) 5 (13.2%) 9 (64.3%) <0.001 







Table 8: Tumour size, prolactin levels and hormone abnormalities at diagnosis and 







   Microprolactinoma  Macroprolactinoma  Giant Prolactinoma







Microprolactinoma  Macroprolactinoma  Giant Prolactinoma
Figure 2: prevalence of hypothyroidism at diagnosis and after treatment in various 






    Microprolactinoma  Macroprolactinoma  Giant Prolactinoma




Data capture sheet 
Patient sticker 
Age at presentation …………………………… Current 
age………………………………. 
Clinical presentation 
Apoplexy Y / N Incidental finding Y / N Altered vision Y / N 
Symptoms 
Headache Y / N 
Visual field defect  Y / N 
Cranial nerve palsy  Y / N 
Galactorrhea  Y / N 
Incidental finding Y / N 
Amenorrhea  Y / N 
Diagnosis  
Prolactinoma 













At diagnosis Y / N Y / N Y / N 
Last follow up Y / N Y / N Y / N 
Management of primary diagnosis 
1. Medical  Y / N Type 
2. Surgery Y / N Procedure 
3. Radiotherapy Y / N Procedure ______ 
Outcome 
Improvement in vision Y / N / NA Cure Y / N / NA 
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Ethics approval 
Signature Removed
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